Piperlonguminine is a potential novel therapeutic agent for Alzheimer's disease.  Extracellular deposits of A-beta in senile plaques of the cerebral cortex are known to be hallmarks of Alzheimer's disease. Recent studies show that a mix of piperlonguminine and dihydropiperlonguminine significantly inhibit the expression of Amyloid Precursor Protein (APP). The decreased production of the peptide Amyloid-beta (A-beta) in SK-N-SH cells is...